Neoplasms

Digestive System Diseases

Gland and Hormone Related Diseases

All Conditions

Symptoms and General Pathology

Rare Diseases

Pancreatic Neoplasms

Postoperative Complications

Pancreatic Diseases

Gastrointestinal Neoplasms

Digestive System Neoplasms

Endocrine Gland Neoplasms

Gastrointestinal Diseases

Endocrine System Diseases

Pancreatic Cancer

Ropivacain-infusion 2 mg/ml 1,25ml/h/10kg IBW (ideal body weight) is started to patients in the beginning of the surgery and is continued to POD 4. The rest of the treatment obey study protocol in both groups.

Analgesia via epidural catheter

Ropivacain 5 mg/ml 2,5ml/10kg IBW (ideal body weight) is given to patients in the end of the surgery. After that ropivacain-infusion 2mg/ml 1,25ml/h/10kg IBW is started to patients and is continued to POD 4. The rest of the treatment obey study protocol in both groups.

Analgesia via wound catheter

Piia Peltoniemi, M.D.

Pertti Pere, Ass.Prof

Pertti Pere, M.D, docent

Hanna Seppänen, Ass.Prof

Teija Nieminen, M.D

Arto Kokkola, Ass.Prof

The study is a randomised controlled trial comparing the effectivity and impact of epidural analgesia and wound catheter analgesia in patients undergoing pancreaticoduodenectomy. The aim of the study is to examine whether there are a difference in perioperative fluid therapy and complication rates between the patients in epidural and wound catheter groups.

All patients undergoing pancreaticoduodenectomy in Helsinki University Hospital are recruited in the study. Patients meeting the inclusion criteria and giving consent to participate the study will be randomised to whether epidural analgesia group or wound catheter analgesia group. Both groups get additional analgesia with intravenous PCA-oxycodone (patient controlled analgesia).

Improvement of Care of Patients Undergoing Pancreaticoduodenectomy

The amount of fluid (crystalloids and albumin) patients have got during the surgery and postoperatively (ml/kg).

The amount of norepinephrine patients have got intraoperatively and postoperatively (mg/kg).

The amount of oxycodone patients have dosed via i.v. PCA pump (mg).

Clavien-Dindo complications (scale 0-5), pancreatic fistulas (ISGPF definition, grade A-C), postpancreatectomy hemorrage (IPGPS definition, grade A-C), delayed gastric emptying (ISGPS definition, grade A-C).

University of Helsinki

Helsinki University Central Hospital

M.D., Principal Investigator

Skin and Connective Tissue Diseases

Breast Neoplasms

Antipyretics

Analgesics

All Drugs and Chemicals

Anticonvulsants

Central Nervous System Depressants

Psychotropic Drugs

Acetaminophen

Gabapentin

Patients cared for prior to the implementation of the Enhanced Recovery after surgery for total mastectomy pathway

patients cared for after the implementation of the Enhanced Recovery after surgery for total mastectomy pathway. Pathway included preoperative acetaminophen and gabapentin, Pec blocks, multimodal analgesia postoperatively and aggressive PONV treatment.

Enhanced Recovery after Surgery (ERAS) pathway for Total Mastectomy

ERAS pathway for Total Mastectomy

Retrospective analysis of pre and post-Enhanced Recovery after Surgery for Total mastectomy pathway implementation.

Retrospective analysis of pre- and post-Enhanced Recovery after surgery for total mastectomy pathway implementation in patients at Mount Zion Hospital. We examined perioperative opioid consumption, pain scores, post-operative nausea and vomiting, benzodiazepine use, length of stay for the time period before and after implementation of an Enhanced Recovery after Surgery pathway for Total mastectomy. Pathway features included preoperative acetaminophen and gabapentin, minimizing opioids, postoperative NSAIDs, Pecs blocks, and aggressive postoperative nausea and vomiting prophylaxis.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Improvement of Care of Patients Undergoing Pancreaticoduodenectomy	NCT04668781	Pancreatic Dise... Pancreas Cancer	Analgesia via e... Analgesia via w...	18 Years - 90 Years	Helsinki University Central Hospital
Efficacy of Enhanced Recovery After Surgery Pathway for Total Mastectomy	NCT03181139	Mastectomy Breast Cancer F...	ERAS pathway fo...	18 Years -	University of California, San Francisco
Efficacy of Enhanced Recovery After Surgery Pathway for Total Mastectomy	NCT03181139	Mastectomy Breast Cancer F...	ERAS pathway fo...	18 Years -	University of California, San Francisco
Improvement of Care of Patients Undergoing Pancreaticoduodenectomy	NCT04668781	Pancreatic Dise... Pancreas Cancer	Analgesia via e... Analgesia via w...	18 Years - 90 Years	Helsinki University Central Hospital
Efficacy of Enhanced Recovery After Surgery Pathway for Total Mastectomy	NCT03181139	Mastectomy Breast Cancer F...	ERAS pathway fo...	18 Years -	University of California, San Francisco

Spots Global Cancer Trial Database for enhanced recovery after surgery (eras)